When one thinks of counterfeit goods, it can conjure up images of customers being duped into buying inferior quality designer bags or other fashion knockoffs. However, when it comes to the manufacturing, distribution and sale of counterfeit medications, the outcomes can be much more serious and life threatening. Most consumers probably don’t realize that counterfeit […]
Our food supply chain typically delivers an affordable and dizzying smorgasbord of flavor, texture, and variety that satisfies consumers. Food that makes us ill is atypical. Fortunately the Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) are on the job to prevent, or at least minimize, the damage from contaminated or […]
About thirty years ago, generic (unbranded) drugs were first approved by the Federal Drug Administration (FDA) for use by patients. These drugs provided competitive alternatives to more expensive name branded pharmaceuticals, and this competition saved consumers $1.68 trillion (not billion) over the last decade, according to the FDA’s Deputy Commissioner. Lower prices from these alternatives […]
CRISPR is an innovation in genetic engineering expected to accelerate cures and therapies for gene-related problems. Along the way, CRISPR will rekindle ethical controversies. How the US handles these controversies will be key to harvesting the benefits of genetic engineering. CRISPR allows scientists to precisely cut out and replace DNA in genes. It has proven […]
When it comes to drug prices, what’s dominating the headlines is bad news story after bad news story. Turing Pharmaceuticals raised the price of an old AIDS drug by more than 5,000 percent overnight, and Valeant Pharmaceuticals International raised a blood pressure drug price by nearly 3,000 percent since 2013, among other consumer losing examples. […]
The recent approval of the first biosimilar drug by the FDA will mark the beginning of competition for a class of lifesaving medicines in the U.S., after nearly a decade of availability in Europe and elsewhere. This ConsumerGram will explore how the pending introduction of competition for biologic drugs will lead to immense consumer benefits, both […]
In November 2013, the FDA ordered a medical testing upstart named 23andMe to halt selling its $99 genetic testing service to consumers until it could prove the tests were reliable. By February 2015, 23andMe was vindicated and able to sell at least some testing. The FDA announced that it will allow patients to get partial […]
ACI’s letter to the FDA is downloadable in PDF format.
ACI’s Capitol Hill event, held of December 9, 2014, discussed the importance of speeding market entry to permit biosimilar competition. That competition would give consumers increased access to lower priced medicine, which would lead to better patient outcomes. Watch the event of the event.
WASHINGTON, Dec. 9, 2014 /PRNewswire-USNewswire/ — The American Consumer Institute Center for Citizen Research (ACI) today hosted an event on Capitol Hill bringing together a panel of experts highlighting the dramatic benefits that unimpeded biosimilars competition would mean for both patients and taxpayers. The event was held as the Food and Drug Administration (FDA) is […]